E. Stambolliu

Treatment Patterns, Disease Management, and Quality of Life in Outpatients with CKD and Decreased eGFR: A Multicenter Prospective Observational Study in Greece

Background/Objectives: Chronic kidney disease (CKD) is a major cause of morbidity and mortality. Evidence on routine management and patient-reported outcomes in Greece is limited. The SPIRIT study assessed real-world treatment patterns, disease management, and quality of life (QoL) among CKD patients in Greece. Methods...

Endothelin receptor antagonism for resistant hypertension in chronic kidney disease: where does aprocitentan fit?

Resistant hypertension, defined as blood pressure (BP) above target despite maximally tolerated doses of at least three antihypertensive agents, including a diuretic, after excluding pseudo-resistance, is common in chronic kidney disease (CKD), and is associated with persistently low rates of BP control [ 1 , 2 ]. Unco...

New pharmacologic and interventional horizons in hypertension and nondialysis chronic kidney disease: bridging innovation and clinical translation.

A comprehensive overview of emerging pharmacologic and interventional approaches for BP management in nondialysis CKD is provided, highlighting mechanism-driven innovations and their potential clinical translation.

Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox.

Nighttime blood pressure versus non-dipping for predicting asymptomatic organ damage in young individuals.

In young individuals asymptomatic HMOD is associated with both nocturnal hypertension and non-dipping, however, nighttime BP levels seem to have the primary contributing role.